Trial: 202102069

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Phase

I

Principal Investigator

Mehta-Shah, Neha

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov